Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Tura-Ceide, Olga
• dc.contributor.author Blanco, Isabel
• dc.contributor.author Garcia-Lucio, Jéssica
• dc.contributor.author del Pozo, Roberto
• dc.contributor.author García, Agustín Roberto
• dc.contributor.author Ferrer, Elisabet
• dc.contributor.author Crespo, Isabel
• dc.contributor.author Rodríguez Chiaradia, Diego Agustín
• dc.contributor.author Simeon-Aznar, Carmen Pilar
• dc.contributor.author López-Meseguer, Manuel
• dc.contributor.author Martín-Ontiyuelo, Clara
• dc.contributor.author Peinado, Victor I.
• dc.contributor.author Barberà, Joan Albert
• dc.date.accessioned 2022-05-25T07:28:30Z
• dc.date.available 2022-05-25T07:28:30Z
• dc.date.issued 2021
• dc.description.abstract Background: Endothelial dysfunction is central to PAH. In this study, we simultaneously analysed circulating levels of endothelial microvesicles (EMVs) and progenitor cells (PCs) in PAH and in controls, as biomarkers of pulmonary endothelial integrity and evaluated differences among PAH subtypes and as a response to treatment. Methods: Forty-seven controls and 144 patients with PAH (52 idiopathic, 9 heritable, 31 associated with systemic sclerosis, 15 associated with other connective tissue diseases, 20 associated with HIV and 17 associated with portal hypertension) were evaluated. Forty-four patients with scleroderma and 22 with HIV infection, but without PAH, were also studied. Circulating levels of EMVs, total (CD31+CD42b-) and activated (CD31+CD42b-CD62E+), as well as circulating PCs (CD34+CD133+CD45low) were measured by flow cytometry and the EMVs/PCs ratio was computed. In treatment-naïve patients, measurements were repeated after 3 months of PAH therapy. Results: Patients with PAH showed higher numbers of EMVs and a lower percentage of PCs, compared with healthy controls. The EMV/PC ratio was increased in PAH patients, and in patients with SSc or HIV without PAH. After starting PAH therapy, individual changes in EMVs and PCs were variable, without significant differences being observed as a group. Conclusion: PAH patients present disturbed vascular homeostasis, reflected in changes in circulating EMV and PC levels, which are not restored with PAH targeted therapy. Combined measurement of circulating EMVs and PCs could be foreseen as a potential biomarker of endothelial dysfunction in PAH.
• dc.format.mimetype application/pdf
• dc.identifier.citation Tura-Ceide O, Blanco I, Garcia-Lucio J, Del Pozo R, García AR, Ferrer E, et al. Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response. Cells. 2021 Jul 4;10(7): 1688. DOI: 10.3390/cells10071688
• dc.identifier.doi http://dx.doi.org/10.3390/cells10071688
• dc.identifier.issn 2073-4409
• dc.identifier.uri http://hdl.handle.net/10230/53251
• dc.language.iso eng
• dc.publisher MDPI
• dc.rights Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword PAH-specific treatment
• dc.subject.keyword Biomarkers
• dc.subject.keyword Endothelial dysfunction
• dc.subject.keyword Endothelial extracellular vesicles
• dc.subject.keyword Progenitor cells
• dc.subject.keyword Pulmonary arterial hypertension
• dc.title Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion